ZNF143 mediates basal and tissue-specific expression of human transaldolase.
Transaldolase regulates redox-dependent apoptosis through controlling NADPH and ribose 5-phosphate production via the pentose phosphate pathway. The minimal promoter sufficient to drive chloramphenicol acetyltransferase reporter gene activity was mapped to nucleotides -49 to -1 relative to the transcription start site of the human transaldolase gene. DNase I footprinting with nuclear extracts of transaldolase-expressing cell lines unveiled protection of nucleotides -29 to -16. Electrophoretic mobility shift assays identified a single dominant DNA-protein complex that was abolished by consensus sequence for transcription factor ZNF143/76 or mutation of the ZNF76/143 motif within the transaldolase promoter. Mutation of an AP-2alpha recognition sequence, partially overlapping the ZNF143 motif, increased TAL-H promoter activity in HeLa cells, without significant impact on HepG2 cells, which do not express AP-2alpha. Cooperativity of ZNF143 with AP-2alpha was supported by supershift analysis of HeLa cells where AP-2 may act as cell type-specific repressor of TAL promoter activity. However, overexpression of full-length ZNF143, ZNF76, or dominant-negative DNA-binding domain of ZNF143 enhanced, maintained, or abolished transaldolase promoter activity, respectively, in HepG2 and HeLa cells, suggesting that ZNF143 initiates transcription from the transaldolase core promoter. ZNF143 overexpression also increased transaldolase enzyme activity. ZNF143 and transaldolase expression correlated in 21 different human tissues and were coordinately upregulated 14- and 34-fold, respectively, in lactating mammary glands compared with nonlactating ones. Chromatin immunoprecipitation studies confirm that ZNF143/73 associates with the transaldolase promoter in vivo. Thus, ZNF143 plays a key role in basal and tissue-specific expression of transaldolase and regulation of the metabolic network controlling cell survival and differentiation.
Grossman
Craig E
CE
Department of Medicine, State University of New York, Upstate Medical University, College of Medicine, 750 East Adams Street, Syracuse, NY 13210, USA.
Qian
Yueming
Y
Banki
Katalin
K
Perl
Andras
A
D020816:Amino Acid Motifs; D017209:Apoptosis; D001483:Base Sequence; D001665:Binding Sites; D001667:Binding, Competitive; D015153:Blotting, Western; D002454:Cell Differentiation; D002460:Cell Line; D045744:Cell Line, Tumor; D002470:Cell Survival; D015500:Chloramphenicol O-Acetyltransferase / Q000378:metabolism; D002843:Chromatin / Q000378:metabolism; D004247:DNA / Q000737:chemistry; D004268:DNA-Binding Proteins / Q000378:metabolism / Q000502:physiology*; D003850:Deoxyribonuclease I / Q000378:metabolism; D017353:Gene Deletion; D005799:Genes, Dominant; D017930:Genes, Reporter; D006367:HeLa Cells; D006801:Humans; D019169:Jurkat Cells; D051741:Kruppel-Like Transcription Factors; D008969:Molecular Sequence Data; D009154:Mutation; D009841:Oligonucleotides / Q000737:chemistry / Q000378:metabolism; D010084:Oxidation-Reduction; D010957:Plasmids / Q000378:metabolism; D011233:Precipitin Tests; D011401:Promoter Regions, Genetic; D015398:Signal Transduction; D014018:Tissue Distribution; D015534:Trans-Activators / Q000378:metabolism / Q000502:physiology*; D014153:Transaldolase / Q000096:biosynthesis* / Q000378:metabolism; D050656:Transcription Factor AP-2; D014157:Transcription Factors / Q000378:metabolism; D014158:Transcription, Genetic; D014162:Transfection; D015854:Up-Regulation
D002843:Chromatin; D004268:DNA-Binding Proteins; D051741:Kruppel-Like Transcription Factors; D009841:Oligonucleotides; C493673:TFAP2A protein, human; D015534:Trans-Activators; D050656:Transcription Factor AP-2; D014157:Transcription Factors; C114253:ZNF143 protein, human; C114252:ZNF76 protein, human; D004247:DNA; D014153:Transaldolase; D015500:Chloramphenicol O-Acetyltransferase; D003850:Deoxyribonuclease I